The present invention relates to an immortalized human neural precursor cell line, NGC-407. The cell line has been established from human foetal tissue. The cell line has been immortalized using a retroviral vector containing the v-myc oncogene. The cell line is a neural progenitor cell line capable
The present invention relates to an immortalized human neural precursor cell line, NGC-407. The cell line has been established from human foetal tissue. The cell line has been immortalized using a retroviral vector containing the v-myc oncogene. The cell line is a neural progenitor cell line capable of differentiating into to astrocytes and neurons including dopaminergic neurons. NGC-407 cells are capable of migrating to glioblastoma tumours implanted into rat brains and form gap junctions with the tumour cells. NGC-407 cells expressing a suicide gene can be be used for delivering activated prodrugs in the form of activated nucleoside analogs to tumours.
대표청구항▼
1. The isolated human NGC-407 cell line deposited under the Budapest Treaty with Deutsche Sammlung von Mkroorganismen and Zellkulturen, on 31 Mar., 2005, under accession number DSM ACC2718 or an isolated cell line obtainable therefrom. 2. The isolated cell line of claim 1, being a polyclonal cell li
1. The isolated human NGC-407 cell line deposited under the Budapest Treaty with Deutsche Sammlung von Mkroorganismen and Zellkulturen, on 31 Mar., 2005, under accession number DSM ACC2718 or an isolated cell line obtainable therefrom. 2. The isolated cell line of claim 1, being a polyclonal cell line. 3. The isolated cell line of claim 1, being a monoclonal cell line. 4. The isolated cell line of claim 1, being transfected or transduced with an expression construct capable of directing the expression of a heterologous therapeutic gene. 5. The isolated cell line of claim 4, wherein the heterologous gene encodes a therapeutic polypeptide. 6. The isolated cell line of claim 4, wherein the heterologous gene comprises a suicide gene. 7. The isolated cell line of claim 6, wherein the suicide gene encodes a polypeptide selected from the group consisting of: a. a deoxyribonucleoside kinase having the amino acid sequence of any of SEQ ID No 1 to 17;b. a polypeptide comprising an amino acid sequence having at least 95% sequence identity to any of SEQ ID No 1, 4, 6, 7, or 17, wherein the amino acid sequence has deoxyribonucleoside kinase activity; andc. a polypeptide comprising an amino acid sequence having at least 90% sequence identity to any of SEQ ID No 2, 3, 5, 8, or one of 9-16, wherein the amino acid sequence has deoxyribonucleoside kinase activity. 8. The isolated cell line of claim 7, wherein the suicide gene encodes a polypeptide selected from the group consisting of: a. a deoxyribonucleoside kinase having the amino acid sequence of any of SEQ ID No 1 to 5;b. a polypeptide comprising an amino acid sequence having at least 95% sequence identity to SEQ ID No 1 or 4, wherein the amino acid sequence has deoxyribonucleoside kinase activity; andc. a polypeptide comprising an amino acid sequence having at least 90% sequence identity to any of SEQ ID No 2, 3, or 5, wherein the amino acid sequence has deoxyribonucleoside kinase activity. 9. The isolated cell line of claim 4, wherein the heterologous therapeutic gene encodes a neurotrophic factor. 10. The isolated cell line of claim 2, in which the heterologous therapeutic gene is encoding a neuronal survival factor. 11. The isolated cell line of claim 2, in which the heterologous therapeutic gene is encoding a nerve growth factor. 12. The isolated cell line of claim 2, in which the heterologous therapeutic gene is encoding a biologically active molecule that participates in the synthesis of a neurotransmitter substance. 13. The isolated cell line of claim 12, in which the neurotransmitter substance is acetylcholine, noradrenaline, adrenaline, 3,4-dihydroxyphenylalanine (L-DOPA), dopamine, octopamine, glutmate, aspartate, glycine, proline, χ-aminobutyric acid (GABA), tyrosine, taurine, alamine, cystathione, histamine, serotonine (5-hydroxytryptamine), substance P, Neuropeptid Y (NPY), Cholecystokinin, neurotensin, enkephalins, or somatostatin. 14. The isolated cell line of claim 2, in which the heterologous therapeutic gene is encoding a receptor. 15. The isolated cell line of claim 6, in which the suicide gene is a thymidine kinase (TK) gene. 16. The isolated cell line of claim 1, being capable of differentiating into astrocytes. 17. The cell line of claim 1, being capable of differentiating into neurons, such as dopaminergic neurons. 18. The cell line of claim 1, being capable of differentiating into glia. 19. The isolated cell line of claim 1, being capable of growing as an adherent culture. 20. The isolated cell line of claim 9, wherein the neurotrophic factor is a Nerve Growth Factor (NGF), an Insulin-like Growth Factor (IGF), a member of the Transforming Growth Factor (TGF) superfamily, Neurturin (NTN), Persephin (PSP); a Glial cell-line Derived Neurotrophic Factor (GDNF); Neublastin (NBN); a Ciliary Neurotrophic Factor (CNTF); a Brain Derived Neurotrophic Factor (BDNF); a Neurotrophin (NT), or a Tumor Necrosis Factor (TNF). 21. The cell line of claim 10, in which the neuronal survival factor is a Super Oxide Dismutase (SOD) or a Hedgehog. 22. The cell line of claim 11, in which the nerve growth factor is a Fibroblast Growth Factor (FGF), an Endothelial Growth Factor (EGF), an interferon, or an interleukin (IL). 23. The cell line of claim 12, in which the biologically active molecule that participates in the synthesis of a neurotransmitter substance is a choline acetyl transferase; a Tyrosine Hydroxylase (TH); a tyrosine decarboxylase; a thymidine kinase, a cytosine deamidase, a monoamine oxidase, a L-DOPA decarboxylase, a histidine decarboxylase, a glutamate decarboxylase, or an Ornithine Transcarbamylase (OTC). 24. The cell line of claim 14, in which the receptor binds acetylcholine, noradrenaline, adrenaline, 3,4-dihydroxyphenylalanine (L-DOPA), dopamine, octopamine, glutamate, aspartate, glycine, proline, .chi.-aminobutyric acid (GABA), tyrosine, taurine, alanine, cystathione, histamine, serotonine(5-hydroxytryptamine), substance P, Neuropeptid Y (NPY), Cholecystokinin, neurotensin, enkephalins, or somatostatin. 25. The cell line of claim 15, in which thymidine kinase (TK) gene is Herpes Simplex Virus thymidine kinase gene, the cytomegalovirus thymidine kinase gene, the varicella-zoster virus thymidine kinase gene the Gpt gene, or the cytosine deaminase gene. 26. The isolated cell line of claim 17, being capable of differentiating into dopaminergic neurons.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (24)
Weng Tao ; David H. Rein ; Brenda J. Dean ; Paul F. Stabila ; Moses B.I. Goddard, ARPE-19 as a platform cell line for encapsulated cell-based delivery.
Baetge Edward E. (Barrington RI) Hammang Joseph P. (Barrington RI) Gentile Frank T. (Warwick RI) Lindner Mark D. (Bristol RI) Winn Shelley R. (Smithfield RI) Emerich Dwaine F. (Providence RI), Compositions and methods for the delivery of biologically active molecules using cells contained in biocompatible capsul.
Baetge Edward E. (Barrington RI) Hammang Joseph P. (Barrington RI) Gentile Frank T. (Warwick RI) Lindner Mark D. (Bristol RI) Winn Shelley R. (Smithfield RI) Emerich Dwaine F. (Providence RI), Delivery of biologically active molecules using cells contained in biocompatible immunoisolatory capsules.
Aebischer Patrick ; Goddard Moses ; Moldauer John G. ; Mulhauser Paul J. ; Rathbun Anne M. ; Sanberg Paul R. ; Vasconcellos Alfred V. ; Warner Nicholas F., Implantable therapy systems and methods.
Aebischer Patrick (Providence RI) Winn Shelley R. (Providence RI) Galletti Pierre M. (Providence RI), In vivo delivery of neurotransmitters by implanted, encapsulated cells.
Mills John F. ; Doherty Edward J. ; Hazlett Tyrone F. ; Dionne Keith E. ; Warner Nicholas F. ; Cain Brian M. ; Rein David H., Method and apparatus for sealing implantable membrane encapsulation devices.
Aebischer Patrick (Barrington RI) Wahlberg Lars (Gvle SEX), Method and system for encapsulating cells in a tubular extrudate in separate cell compartments.
Schinstine Malcolm ; Shoichet Molly S.,CAX ; Gentile Frank T. ; Hammang Joseph P. ; Holland Laura M. ; Cain Brian M. ; Doherty Edward J. ; Winn Shelley R. ; Aebischer Patrick,CHX, Method for controlling proliferation and differentiation of cells encapsulated within bioartificial organs.
Holland Laura M. (Providence RI) Hammang Joseph P. (Barrington RI) Rudnick Seth A. (Barrington RI) Lysaght Michael J. (E. Greenwich RI) Dionne Keith E. (Rehoboth MA), Method for implanting encapsulated cells in a host.
Dionne Keith E. ; Emerich Dwaine F. ; Hoffman Diane ; Sanberg Paul R. ; Christenson Lisa ; Hegre Orion D. ; Scharp David W. ; Lacy Paul E. ; Aebischer Patrick,CHX ; Vasoohcellos Alfred V. ; Lysaght M, Methods for making immunoisolatary implantable vehicles with a biocompatible jacket and a biocompatible matrix core.
Aebischer Patrick (Barrington RI) DiCesare Paul C. (Norwalk CT) Goddard Moses (Tiverton RI) Mulhauser Paul J. (New York NY), Renewable neural implant device and method.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.